Article

Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation.

Division of Blood and Marrow Transplantation, Stanford University, Stanford, California 94305, USA.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (Impact Factor: 3.35). 01/2011; 17(1 Suppl):S58-62. DOI: 10.1016/j.bbmt.2010.10.020
Source: PubMed
Download full-text

Full-text

Available from: Lucrezia Colonna, Jul 04, 2015
0 Followers
 · 
122 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Template-matching is the least sophisticated and most compute-intensive part of automatic target recognition (ATR) processing for synthetic aperture radar (SAR) applications. Complexity considerations dictate the use of low template densities in target signature space, while the extreme sensitivity of correlation processing to pose mandates the averaging of templates over a range of pose angles to achieve some generalization. Thus, the templates considered in ATR systems are often generated by noncoherently averaging target templates within a five degree pose-angle window, resulting in poor correlation gain. In this paper, we propose to dramatically increase the computational efficiency of correlation-based reasoning, using a completely different paradigm-the bit-ordered tree classifier (BOTC)-to enable high-density, high-confidence matching. Instead of performing, for example, 8-bit correlation between template and test images and comparing to a threshold, the BOTC makes selected binary comparisons to reach the same acceptance/rejection decisions with comparable operational characteristics, using far fewer computations. We report up to a two orders of magnitude speedup, compared to 8-bit correlation in preliminary testing on SAR target data from the MSTAR collection. We also investigate the efficient mapping of our novel BOTC technique to adaptive computing platforms such as field programmable gate arrays (FPGAs).
    Signals, Systems & Computers, 1997. Conference Record of the Thirty-First Asilomar Conference on; 12/1997
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stromal cells (MSCs) represent a heterogeneous subset of multipotent cells that can be isolated from several tissues including bone marrow and fat. MSCs exhibit immunomodulatory and anti-inflammatory properties that prompted their clinical use as prevention and/or treatment for severe graft-versus-host disease (GVHD). Although a number of phase I-II studies have suggested that MSC infusion was safe and might be effective for preventing or treating acute GVHD, definitive proof of their efficacy remains lacking thus far. Multicenter randomized studies are ongoing to more precisely assess the impact of MSC infusion on GVHD prevention/treatment, whereas further research is performed in vitro and in animal models with the aims of determining the best way to expand MSCs ex vivo as well as the most efficient dose and schedule of MSCs administration. After introducing GVHD, MSC biology, and results of MSC infusion in animal models of allogeneic hematopoietic cell transplantation, this article reviews the results of the first clinical trials investigating the use of MSC infusion as prevention or treatment of GVHD.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 09/2011; 18(6):822-40. DOI:10.1016/j.bbmt.2011.09.003 · 3.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: We investigated the ability of clinical-grade enriched human regulatory T cells (Treg) to attenuate experimental xenogeneic graft-versus-host disease (GVHD) induced by peripheral blood mononuclear cells (PBMNCs; autologous to Treg) infusion in NSG mice, as well as verified their inability to induce xenogeneic GVHD when infused alone. STUDY DESIGN AND METHODS: Human Treg were isolated from peripheral blood apheresis products with a cell separation system (CliniMACS, Miltenyi Biotec GmbH) using a two-step procedure (simultaneous CD8 and CD19 depletion followed by CD25-positive selection) in six independent experiments with six different healthy volunteer donors. Sublethally (2.5 Gy) irradiated NSG mice were given 2 × 10(6) cytapheresis (PBMNC) product cells intravenously (IV) without (PBMNC group) or with 1 × 10(6) Treg (PBMNC + Treg group), while other NSG mice received 2 × 10(6) enriched Treg alone (also in IV; Treg group). RESULTS: The first five procedures were successful at obtaining a relatively pure Treg population (defined as >50%), while the sixth procedure, due to a technical problem, was not (Treg purity, 42%). Treg cotransfusion significantly delayed death from xenogeneic GVHD in the first five experiments, (p < 0.0001) but not in the sixth experiment. Importantly, none of the mice given enriched Treg alone (Treg group) experienced clinical signs of GVHD, while, interestingly, the CD4+ cells found in these mice 26 days after transplantation were mainly conventional T cells (median CD25+FoxP3+ cells among human CD4+ total cells were only 2.1, 3.1, and 12.2% in spleen, marrow, and blood, respectively). CONCLUSIONS: Infusion of clinical-grade enriched Treg delayed the occurrence of xenogeneic GVHD without inducing toxicity in this murine model.
    Transfusion 06/2013; 54(2). DOI:10.1111/trf.12279 · 3.57 Impact Factor